vida: extract claims from 2026-04-29-mssp-health-affairs-2024-aco-participation-trends

- Source: inbox/queue/2026-04-29-mssp-health-affairs-2024-aco-participation-trends.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression.md

@@ -46,3 +46,10 @@ Eli Lilly Employer Connect launched March 5, 2026 at $449/dose with partnerships
 **Source:** HR Brew/PR Newswire Q4 2025-Q1 2026 DTE announcements
 
 Both major GLP-1 manufacturers (Eli Lilly via Employer Connect, Novo Nordisk via 9amHealth/Waltz Health partnerships) now operate DTE channels as of Q1 2026. Novo's Waltz Health DTE program launched January 1, 2026 for FDA-approved obesity medications. 9amHealth's No-Barriers Bundle integrates access to medications from both manufacturers at fixed monthly costs. However, neither manufacturer has disclosed enrollment data or market penetration, and expert consensus characterizes DTE as 'manufacturers positioning themselves as more active participants in employer access strategy' rather than structural displacement of PBM intermediation.
+
+
+## Challenging Evidence
+
+**Source:** MedCity News / National Alliance expert assessment, March 2026
+
+Lilly Employer Connect's $449/month net price for Zepbound 'doesn't appear to be substantially lower than the price employers were already getting' through existing PBM channels according to National Alliance of Healthcare Purchaser Coalitions expert. Big Three PBMs (CVS Caremark, OptumRx, Express Scripts) still control approximately 80% of US prescription claims. The DTE channel represents a 'governance shift rather than structural disruption' per Sequoia analysis - manufacturers becoming direct participants in employer benefit design rather than achieving price disruption.

domains/health/mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: Payers actively raise reimbursement to attract medical providers when network gaps exist but do not apply the same methodology to mental health provider networks, creating a structural mechanism that perpetuates access barriers independent of coverage mandates
+confidence: experimental
+source: DOL EBSA, 2025 MHPAEA Report to Congress
+created: 2026-04-29
+title: MHPAEA enforcement closes coverage gaps but not access gaps because payers differentially treat mental health versus medical reimbursement rates
+agent: vida
+sourced_from: health/2026-04-29-mhpaea-fourth-report-2025-enforcement-structural-limits.md
+scope: structural
+sourcer: DOL EBSA
+related: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access"]
+---
+
+# MHPAEA enforcement closes coverage gaps but not access gaps because payers differentially treat mental health versus medical reimbursement rates
+
+The 2025 MHPAEA Report to Congress documents a specific structural mechanism explaining why mental health parity enforcement improves coverage mandates without closing access gaps. EBSA found multiple instances where plan sponsors and issuers 'actively increased reimbursement rates for certain M/S [medical/surgical] providers as a strategy to attract and retain service providers where they found insufficiency in the network' but 'the same methodologies were NOT utilized to attract and retain MH/SUD providers, even where gaps were identified in MH/SUD provider networks.' This is not passive neglect or ignorance—it is documented differential treatment at the operational level. Payers demonstrate they know how to fix network adequacy problems (raise reimbursement rates) and actively deploy this strategy for medical networks, but deliberately choose not to apply it to mental health networks. This creates a structural barrier that persists independently of coverage mandates: even when plans are required to cover mental health services at parity, the supply-side incentive structure remains broken because payers won't pay enough to attract providers. The enforcement actions documented in the report (dozens of actions, $100K-$2M+ penalties) target coverage compliance and NQTL documentation, but cannot compel payers to raise reimbursement rates. The report's focus on enforcement actions without corresponding access outcome metrics (reduced wait times, more in-network providers) suggests that compliance improvements are not translating to access improvements. This mechanism explains why strong enforcement (2024 rule with new NQTL comparative analysis requirements, network adequacy standards, ABA/MAT exclusion coverage mandates) coexists with persistent access barriers.

domains/health/mssp-acos-generate-record-savings-while-improving-quality-proving-cost-quality-cooptimization.md

@@ -17,3 +17,10 @@ related: ["value-based care transitions stall at the payment boundary because 60
 # MSSP ACOs generated record $2.48B in net Medicare savings in 2024 for the eighth consecutive year while maintaining superior quality performance compared to non-ACO peers proving that cost and quality improvement are achievable simultaneously under value-based payment
 
 The 2024 MSSP results provide the strongest empirical evidence that value-based care's structural fix thesis works at scale. ACOs generated $2.48B in net Medicare savings (after shared savings payments) for the eighth consecutive year, with per capita net savings increasing from $207 in 2023 to $241 in 2024. Critically, this cost reduction occurred alongside quality improvements across multiple clinical domains. ACOs outperformed non-ACO physician groups on Screening for Depression and Follow-up Plan (53.53% vs 44.42%), Controlling High Blood Pressure (71.21% vs 67.82%), and showed improved performance on A1c control and cancer screening. This simultaneous cost-quality improvement directly refutes the central critique of value-based care: that cost reduction incentives will lead to under-treatment. The data shows the opposite pattern—ACOs are both more cost-effective AND deliver higher quality care. The acceleration is also notable: per capita gross savings increased $128 year-over-year (from $515 to $643), the largest single-year jump in the program's history. Two-thirds of ACOs now participate in downside risk tracks (Level E or Enhanced), generating $5.4B of the $6.6B in gross savings, demonstrating that the transition to full risk-bearing is advancing despite aggregate payment statistics showing only 14% of total healthcare payments bearing full risk.
+
+
+## Extending Evidence
+
+**Source:** Health Affairs 2024 MSSP analysis
+
+MSSP 2024 performance shows acceleration in per capita savings: $641 gross per capita (up $128 from 2023) and $241 net per capita (up $34 from 2023). This year-over-year increase in per capita savings suggests ACOs are exhibiting learning curve effects - getting better at value-based care over time rather than just selecting healthier populations. The quality improvements are specific and measurable: depression screening 53.5% vs 44.4% for non-ACO peers, blood pressure control 71.2% vs 67.8%, with cancer screening and A1c control also improving. This provides the strongest counter-evidence to the 'VBC under-treats to cut costs' concern - quality is improving alongside cost reduction, not trading off.

domains/health/mssp-downside-risk-adoption-accelerating-two-thirds-in-risk-tracks.md

@@ -16,3 +16,10 @@ related: ["value-based care transitions stall at the payment boundary because 60
 # Two-thirds of MSSP ACOs now participate in downside risk tracks generating more than two-thirds of all savings demonstrating that the transition to full risk-bearing is accelerating despite slow aggregate payment statistics
 
 The MSSP 2024 results reveal a critical structural shift in value-based care adoption that contradicts the narrative of stalled transition. Two-thirds of participating ACOs are now in Level E or Enhanced tracks—both of which include downside risk—and these risk-bearing ACOs generated $5.4B of the $6.6B in total gross savings (82% of all savings). This concentration of savings in risk-bearing arrangements demonstrates that full accountability drives superior performance. The transition is also accelerating institutionally: CMS 2026 rules make two-sided risk the default for new MSSP entrants and restrict one-sided participation, while simultaneously launching the Ambulatory Specialty Model (ASM) for heart failure and low back pain with mandatory risk-bearing. This policy direction directly contradicts the claim that value-based care adoption has stalled. The aggregate statistic showing only 14% of total healthcare payments bearing full risk reflects the SLOW PACE of transition across the entire healthcare system, not a failure of the model itself. Within MSSP—the largest federal value-based care program—the transition to risk-bearing is advancing rapidly, with two-thirds already participating and policy changes forcing the remainder to follow. The gap between MSSP's 67% risk-bearing rate and the healthcare system's 14% rate reveals that the bottleneck is adoption speed and policy will, not model viability.
+
+
+## Extending Evidence
+
+**Source:** Health Affairs 2024 MSSP analysis, CMS 2026 rules
+
+The two-thirds of ACOs now in Level E or Enhanced (downside risk) tracks generated $5.4B of the $6.6B total gross savings (82%), while representing two-thirds of participants. This creates a precise empirical claim: risk-bearing ACOs generate disproportionate savings relative to their share of participation. The 82% savings from 67% of ACOs demonstrates that downside risk adoption is not just growing in volume but is the high-performance tier of the MSSP program. CMS 2026 rules restricting one-sided participation (reducing cap from 7 to 5 years starting 2027) will accelerate this shift further.

inbox/archive/health/2026-04-29-lilly-employer-connect-not-revolutionary-dte-limits.md

@@ -7,10 +7,13 @@ date: 2026-03-05
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-29
 priority: medium
 tags: [GLP-1, direct-to-employer, DTE, PBM, Lilly, employer-coverage, market-competition]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-04-29-mhpaea-fourth-report-2025-enforcement-structural-limits.md

@@ -7,10 +7,13 @@ date: 2026-03-03
 domain: health
 secondary_domains: []
 format: report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-29
 priority: high
 tags: [mental-health, MHPAEA, parity, enforcement, supply-gap, workforce, network-adequacy]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-04-29-mssp-health-affairs-2024-aco-participation-trends.md

@@ -7,10 +7,13 @@ date: 2025-11-05
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-29
 priority: medium
 tags: [ACO, MSSP, Medicare, value-based-care, policy, downside-risk, 2024]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content